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I. INTRODUCTION 
Bronchiolitis is one of the common causes of lower respiratory 
tract infections in infants and young children.Bronchiolitis is a 
predominantly viral disease .The virus which is implicated for more 
than 50% of cases is the respiratory syncytial virus.Other etiological 
agents which are implicated in bronchiolitis include parainfluenza, 
adenovirus and mycoplasma.Other new pathogens which are 
implicated include human boca virus, and the human 
metapneumovirus. 
The human Bocavirus can occur as a coinfection with 
respiratory syncytial virus. Bronchiolitis mainly occurs during august 
through november which coincides with respiratory syncytial virus 
season.The period of infectivity in cases of respiratory syncytial virus 
is 3 days before to 21 days after onset of symptoms. 
There are host factors too which have to be considered in case 
of bronchiolitis.For example bronchiolitis is more commoner in boys 
than girls.It is more  in infants who are deprived of breast milk.It is 
also more common in overcrowded conditions.The prevalence of 
bronchiolitis is more in cases of mothers who smoke during 
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pregnancy.Younger mothers too have a higher risk of having a child 
with bronchiolitis. 
The clinical manifestation of bronchiolitis is more severe in 
young infants as they poorly tolerate bronchiolar edema compared to 
adults.The immunity of the host too plays a significant role in deciding 
the severity of clinical manifestations.The nature of the virus too plays 
a role. 
There will be severe clinical manifestations if there are pre- 
existing smaller airways and diminished lung function.Innate 
immunity plays a significant role in the pathogenesis of 
bronchiolitis.The cytotoxic damage caused by the eosinophil cationioc 
protein also has a role to play in the pathogenesis of 
bronchiolitis.Interleukins and tumor necrosis factor may be 
differentially expressed depending on the different types of inciting 
agents.If the inciting agent is more than one, that too will affect the 
varied manifestation of bronchiolitis. 
Acute bronchiolitis is due to bronchiolar obstruction which is 
caused by airway edema,mucus collection and cellular debris.Minimal 
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bronchiolar wall thickening will also lead to significant air way 
obstruction because of the inverse relationship between the 
bronchiolar wall and its radius.Resistance in the bronchioles is more 
during inspiration as well as expiration but as the radius is very much 
decreased during expiration there is more and more air trapping in 
cases of bronchiolitis. 
If the obstruction progresses  there will be air trapping leading 
on to development of the atelectasis.Hypoxia and hypercapnia develop 
subsequent to the disease process. 
 The diagnosis of bronchiolitis is mainly a clinical one. 
Bronchiolitis is mainly diagnosed by a constellation of symptoms and 
signs . Depending on the severity of clinical manifestations Indian 
academy of pediatrics has classified bronchiolitis in to  mild, moderate 
and severe disease. 
 In cases of mild bronchiolitis the infant will have a normal 
ability to feed and the oxygen saturation will be more than ninety two 
percent. 
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In cases of moderate bronchiolitis the infant will have shortness 
of breath during feeding,moderate distress with some chest wall 
retractions and nasal flare will also be there.The oxygen saturation 
will be less than ninety two percent which is correctable by oxygen. 
In cases of severe cases of bronchiolitis there will be reluctance 
to feed or inability to feed .Severe distress with marked chest wall 
retractions and nasal flare as well as grunting will be there.The 
saturation of oxygen will be less than ninety two percent and it may or 
may not be correctable with oxygen therapy. 
While diagnosing bronchiolitis other conditions in infants and 
young children which present with wheeze must be kept in 
mind.Asthma and allergy present in similar manner and viral 
bronchopneumonia when it presents with wheeze is almost clinically 
indistinguishable from bronchiolitis. 
Foreignbody aspiration too is a common cause of wheeze.Other 
congenital airway anomalies like laryngotracheomalacia have to be 
kept in mind before making a diagnosis of bronchiolitis.Gastro 
esophageal reflux too causes wheeze by virtue of it producing vagal or 
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neural reflex which will increase  airway reactivity and and also 
airway resistance. 
Other chronic causes of wheeze like cystic fibrosis has to be 
kept in mind.Investigational modalities like x ray are mainly used to 
exclude other diagnosis.In bronchiolitis there will be hyperinflation 
which will also be present in cases of viral bronchopneumonia. 
Blood investigations are not routinely performed and they only 
play a role if there is bacterial super added infection.Blood  cultures 
too don’t have a routine role in cases of bronchiolitis. 
The treatment modality in cases of bronchiolitis is largely 
supportive.Mild cases of bronchiolitis can be safely managed at home 
.Even amongst moderate bronchiolitis only children whose saturation 
is below par require inhospital admission and treatment.Severe cases 
require intensive care. 
 Trial of bronchodilators are used in the setting of a clinical 
response after a trial nebulization.If there is no response after 24 hrs 
they are not continued.Intravenous fluids have to be used only if there 
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is significant respiratory distress which prevents  oral 
feeds.Nasogastric feeds can also tried. 
IV fluids does not provide any significant advantage over 
nasogastric feeds.There have been numerous studies investigating the 
various agents used in the treatment of bronchiolitis.None of the tried 
treatments have been proven to significantly alter the course of 
disease. 3% hypertonic saline too has been tried in bronchiolitis and 
found to alter the duration of the disease and clinical severity in some 
studies. 
 Since the main treatment of bronchiolitis is mainly supportive 
we decided to work on the morbidity part and also to find out if there 
is any significant difference in the length of stay. 
Since no broncodilator has a proven benefit in cases of 
bronchiolitis we decided to try nebulised hypertonic saline alone 
without any bronchodilator or epinephrine.And also not many studies 
have been conducted in the Indian context which in many ways are 
quite different from the American or European context when we take 
in to account the environmental,nutritional,immunological as well as 
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the genetic makeup of our population.And also this seemed to be a 
cheap and practically feasible in a developing country like India  
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REVIEW OF LITERATURE 
 Definition: 
Bronchiolitis is defined as per American academy of pediatrics 
definition as a  constellation of clinical symptoms and signs like 
rhinorrhoea, cough, wheezing ,tachypnoea ,and increased respiratory 
effort manifested as grunting, nasal flaring and intercostal and or 
subcostal retractions in children less than 2 years of age. 
Moderate bronchiolitis is characterized by feeding 
difficulty,moderate respiratory distress with some chest wall 
retractions and nasal flaring and oxygen saturation less than 92% 
which is correctable with oxygen.As bronchiolitis is mainly diagnosed 
clinically there is considerable difference amongst clinicians  in its 
diagnosis. 
 There seems to exist a confusion world over regarding the 
diagnostic criteria which have to be used in diagnosis of 
bronchiolitis.Some studies have used tachypnoea and some have used 
wheezing and some have used nasal flare in diagnosis or inclusion 
criteria1.  
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The north Carolina group includes expiratory wheeze in the 
presence or absence of increased respiratory rate, substernal 
retractions along with the feature of air trapping2. 
In United kingdom the diagnosis of bronchiolitis is even more 
confined.It is regarded as a seasonal acute lower respiratory tract 
infection which manifests with coryza in the first two to three days 
then, develops the lower respiratory symptoms.Wheeze associated 
lower respiratory tract infection is also a terminology used .Viruses 
can cause wheeze in bronchial asthma ,viral bronchopneumonias and 
the different outcomes with various treatment modalities can be 
attributed to this3. 
EPIDEMIOLOGY: 
The major fraction present with upper respiratory tract 
manifestations and at about forty percent present with lower 
respiratory tract manifestations.Around one to two percent require 
inpatient care out of which five to ten percent of patients require 
artificial respiration4.The morbidity of bronchiolitis incurs a 
considerable health expenditure on the nation as well as the 
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individual.And repeated episodes of wheezing too occur in case of  
bronchiolitis producing significant functional impairment affecting the 
quality of life of the individual4. 
ETIOLOGY: 
 Apart from respiratory syncytial virus, parainfluenza, human 
boca virus, human metapneumovirus the human corona virus is also 
implicated in the etiology of bronchiolitis.Respiratory syncytial virus 
is an enveloped rna virus.It comprises of a single stranded negative 
sense  genome and multiplication takes place inside the cytosol of a 
cell.The virus is not known to undergo antigenic shift, hence 
reassortment of virions cannot happen which happens in the case of 
influenza virus.It comes under paramyxoviridae family accompanied 
by parainfluenza and measles virus.It belongs to the pneumovirinae 
group which also encompasses human metapneumovirus. 
Two antigenic subtypes of  respiratory syncytial virus are there 
which differs by virtue of their surface proteins.The reinfections 
causing recurrent bronchiolitis is attributed to the point mutations 
which take place with the viral ribonucleic acid polymerase. 
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Respiratory syncytial virus multiplies in cell lines such as the 
Hela or the Hep-2 cell lines leading to the characteristic formation of 
syncytium from which the virus derives its name from.It is not known 
whether the syncytium formation occurs in vitro alone or it occurs in 
the invivo setting too. 
Kneyber et al6 showed that there is no significant difference 
between the two types of respiratory syncytial viruses  which were 
compared.No difference was seen in the duration of stay and the need 
for oxygen as well as the need for intensive care. Zambon et al5 
studied the phylogenetics  of the RSV over a period of three seasons 
and came to the conclusion that they cause the same spectrum of 
manifestations involving the upper as well as lower respiratory tracts 
and caused disease both in children young infants as well as adults 
alike. 
Respiratory syncytial virus causes disease in all age 
groups.Infection is universal by the time children atttain two years of 
age.The manifestations in case of RSV is very much similar to the 
influenza virus hence differentiating between these two etiologies is 
quite cumbersome.However the systemic prodrome features will be 
there in cases of influenza infections.  
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ELECTRON MICROSCOPY PICTURE OF RESPIRATORY 
SYNCYTIAL VIRUS SHOWING THE CHARACTERISTIC 
SYNCYTIUM FORMATION. 
 
Human metapneumovirus is a enveloped single strand 
nonsegmented negative sense ribonucleic acid virus.The human 
metapneumovirus is closely related to avian pneumoviruses .The 
decreased pathogenicity of the metapneumoviruses compared to the 
wild type respiratory syncytial virus is attributed to the difference of 
structural proteins in case of metapneumovirus7. 
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The human metapneumovirus outbreaks coincide with the 
second half of the respiratory syncytial virus season.But infections do 
occur through out the year sporadically.Infection is known to occur by 
virtue of close contact or by aerosolized spread through droplets.  
Nosocomial infections have been reported and isolation of the 
contacts as well as proper hand washing of medical personnel are 
advised.The virus affects individuals with reactive airway disease in a 
more severe manner. Hcov-63 has been isolated from a seven month 
old child with conjuctival infection and bronchiolitis8.Later it was 
isolated from several clinical specimens . 
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PATHOGENESIS: 
 
           
 
 
 
 
 
                                         
 
 
 
 
 
 
 
 
 
 
 
Bronchiolar epithelial necrosis. 
Mucus hypersecretion. 
Edema of submucosa. 
Formation of mucus plugs obstructing 
bronchioles 
Obstruction and collapse of the smaller 
airways during expiration 
Consequent hyperinflation or 
collapse of the distal lung tissue 
Wheezing9 
 15 
 
The airway of young infants typically do not react in a hyper 
responsive manner .Host factors too play a role .The immune response  
itself sometimes affects the host in a detrimental manner.And there is 
evidence to suggest the role of genetic factors also in the severity of 
the disease. 
 The severity of Respiratory syncytial virus infection is more in 
the case of  immunocompetent host compared to a immune 
compromised host.Children who received formalin inactivated RSV 
vaccine experienced more severe symptoms after getting infected by 
wild type of RSV subsequently. Many children died after RSV 
infection postvaccination.This impeded the development of newer 
vaccines for RSV infections.RSV symptoms are more severe when 
the viral multiplication is waning, once more implicating immunity 
in the pathogenesis of RSV infections. 
Several immunological processes are doubted to play a role in 
respiratory syncytial virus infections.The occurrence  of bronchiolitis 
after the primary infection caused by respiratory syncytial virus , the 
development of recurrent wheezing are all due to a complex interplay 
of various agent and host interactions. 
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T-LYMPHOCYTES AND ANTIGEN PRESENTING CELLS : 
An immunological response is mounted by the host against the 
agent so as to eradicate it from the respiratory tract.Respiratory 
syncytial virus specific cluster of differentiation four and eight cells 
are produced. 
If there is insufficient immune response against the virus the 
virus will persist for a longer period.Respiratory syncytial virus 
continues to be shed from the respiratory tract for a duration of 
around nine days in pediatric age group younger than one year of 
age. High levels of the virus might be there in secretions even though 
clinical resolution would have occurred by that time. 
 In HIV affected individuals the virus is shed for a duration of 
around 30 days. When animals were inoculated with specific T-
lymphocytes  in addition to the clinical improvement that happened, 
there was inflammation mediated by these T-lymphocytes thus 
providing the insight, that they do play a very important role in the 
pathogenesis of the disease. They contributed to the hyper 
responsiveness of the air way.These experiments prove that inspite of 
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the role of an effective immune response which helps in clearing the 
infection they also play a role in causing airway injury. 
In murine studies it has been demonstrated that CD-4 T 
lymphocytes which mount an immune response against the fusion 
protein provides the necessary protection against the disease .This is 
accomplished with the help of cytotoxic CD-8 lymphocytes, and also 
with the help of antibody of the igG type. 
Circulating  antibodies of the immunoglobulin G class are 
produced several days after the development of infection. These are 
primarily directed against the fusion proteins of respiratory syncytial 
virus. The proposition that higher levels of antibodies  proved 
detrimental has been proven to be wrong after its beneficial effects 
were observed in the newborns due to the transfer of antibodies 
through the breast milk. And also it was shown that after a first 
attack of the bronchiolitis,the subsequent attacks were of lesser 
severity mainly attributable due the primary immunity acquired after 
the infection. 
CD-4 lymphocytes direct against the g-protein leads to the 
helper cell mediated immune response leading on to the production 
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of interleukins 5 and 10 and a eosinophil influx11. These interleukins 
are thought to be responsible for the hyperresponsiveness which is 
observed. If respiratory syncytial disease is  mediated by helper T 
cells , then there must have been an association with allergic 
component, which has not been proven. 
Lot of cohort studies have been done, but they have failed to 
establish any association between respiratory syncytial virus and 
allergic component12.A study by sigurs et al13 has come out saying 
that respiratory syncytial virius infection leads to sensitization 
against allergens in the air as well as later manifestation of allergy. 
The natural immunity too plays a role in protection  through  
eosinophils,  polymorphs and APC’S. Neutrophil degranulation leads 
to release of substrates which can be easily detected and there is a 
relation between the levels of released substrates and disease 
severity. The mucosa is protected by migration of monocytes as well 
as dendritic cells. These cells might lead on to the development of 
airway hyper responsiveness or they might delay the T cell mediated 
immune response. 
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ROLE OF DUAL INFECTIONS: 
Hament et al14 has proved that a respiratory syncytial virus 
infected respiratory epithelium is easily infected by pneumococcal 
virus. This was shown to be due to the increased binding. And a co- 
infection also leads to a much stronger binding to the respiratory 
epithelium. The effect was related to the dose as well as the different 
strains causing the infection. 
This was supported further by a study from south Africa15 
showing the association of pneumococci with the respiratory 
syncytial virus associated pneumonia. 
Semple et al16 demonstrated that a dual infection with human 
metapneumovirus and respiratory syncytial virus leads to a severe 
disease. The presence of co-infection was found to be seventy two 
percent in a intensive setting amongst bronchiolitis cases compared 
to ten percent in a general ward. 
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ROLE OF GENETICS: 
The genetic component plays a role in affecting the outcome of 
the disease process. This is due to the polymorphisms in the genetic 
components requisite to mount an effective immune response. The 
genetic difference also plays a role in determining the severity of the 
disease. 
Lofgren et al17 provided an insight to the polymorphisms in 
surfactant proteins and respiratory syncytial virus infection. A certain  
haplotype   was shown to produce a more severe disease that is 
6A2/1A3C . 
A difference in polymorphisms of innate immunity too plays a 
role in shaping the course of the disease. Venter et al18 and Bleek et 
al19 showed the difference in the reaction of T lymphocytes to the 
epitopes  G, N and F. 
This despite the fact that the epitopes are largely preserved in 
wild type of respiratory syncytial virus. Venter et al18 showed a 
interferon gamma response in twenty one out of thirty eight 
individuals when challenged with over lapped peptides. This was 
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found to be due to a HLA B8 which was a restricted epitope.  Van 
bleek et al19 showed a significant inter individual variation in the 
interferon gamma production . This was decided by the extent to 
which the epitopes were recognized. 
Tal et al20 studied the polymorphisms in TLR-4 which were 
shown to produce a more severe respiratory syncytial virus disease. 
Severe cases were defined by the need for in hospital and intensive 
care. They were compared with mild bronchiolitis and a group of 
healthy adult population. 
Hull et al21 showed that  interleukin eight 251 A polymorphic 
variations in the genes coding for interleukin eight had a increased 
prevalence in patients with severe degrees of respiratory syncytial 
virus disease. And also this polymorphic variation was shown to be 
associated with the chronic effects of respiratory syncytial virus-
bronchiolitis. 
Hoe bee et al22 studied the polymorphisms in interleukin-four 
,interleukin-4-R,  and interleukin ten. They showed that a   
polymorphism in IL-4 which is a thymidine substitute for cytosine 
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leads on to increase in hospital admissions in case of RSV infections.  
And the association was stronger in babies more than six months of 
age. The interleukin 4Ra-R551 genetic polymorphisms was present 
in more severe manner in babies more than six months of age. 
Similar results was shown by choi et al23 amongst Korean 
population. Hoebee et al22 highlighted that patients homozygous for 
interleukin ten 592 c or interleukin ten 592a could have a clinically 
severe bronchiolitis when compared with a population which is 
heterozygous for the same. 
Wilson et al24 showed a relationship between genetic 
polymorphisms invoving interleukin ten and the increasing need for 
artificial respiration. This homo-heterozygous variation has not been 
studied before. 
Hull et al25 studied the genetic polymorphisms involving the 
interleukin-5 receptor which was said to produce severe 
bronchiolitis.This receptor interacts with MIP 1-A. And it is known 
to produce a vital role in pathway  of bronchiolitis. 
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AGE AND BRONCHIOLITIS: 
Younger the chid more severe is the clinical presentation of 
bronchiolitis especially in infants less tnan six months. Bont et al26 
studied the correlation of post gestational age less than forty four 
with the severity of manifestation of the illness. It’s quite possible 
that younger chidren fail to produce a effective immunological 
response by virtue of interferon gamma production thus leading on to 
a clinically severe disease disease compared to older children. 
Culley et al27 studied in murine models the effect of respiratory 
syncytial virus at two week intervals thus stressing the impotant role 
the age plays in the pathogenesis of bronchiolitis.  Murine models at 
younger age developed a more severe bronchiolitis due to ineffective 
interferon gamma release , instead interleukin four predominates 
leading to hyper reactive response. 
Murine models infected at more advanced gestational age 
showed a stronger interferon gamma release compared to younger 
ages. But the production of interleukin four was more muted. These 
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studies showed the important role that interferon gamma release 
plays as gestational age advances. 
BRONCHIOLITIS AND REACTIVE AIRWAY DISEASE: 
Several works have shown the association between 
bronchiolitis and later development of reactive airway disease. 
Episodic wheeze which follows bronchiolitis develops in forty two to 
seventy one percent of patients, and it occurs mainly in less than two 
year old age group28. Recent studies have shown that repeated 
wheeze following the disease decreases as the child ages, but this 
might be different in patients who have atopy and in those who do 
not have atopy. 
PATHOLOGY OF BRONCHIAL HYPER-REACTIVITY 
AFTER RSV DISEASE: 
Studies have shown the role of T lymphocytes -2 in the hyper 
responsiveness following the disease. In animal models neurotropin 
growth factor has been shown to play a role in hyper responsiveness 
following a episode of the disease. Piedemont et al showed a link 
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between neural stimulation and vascular leakage which is present  
even after the initial phase of the disease. 
Piedemont et al hypothesized that a remodelled airway results 
following an attack of respiratory syncytial virus disease. Animal 
models have shown the persistence of  respiratory syncytial virus in 
the lung despite active t-lymphocyte response. 
Such persistence of RSV leads to the development of 
susceptibility to other infections. It could also lead to development of 
atopy. No definite link has been established between bronchiolitis 
and bronchial asthma at later ages. 
CLINICAL MANIFESTATIONS: 
Almost all less than two years of age get infected with 
respiratory syncytial virus. Fifty percent of the patients get clinically 
significant disease and amongst them a few require in hospital care. 
The disease starts with running nose, fast breathing, breathlessness 
intercostal and subcostal retractions  along with wheeze. 
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There will be decreased oxygen saturation and the chest X-ray 
might reveal bilateral diffuse hyperinflation of lungs , flattening of 
diaphragm , prominence of retrosternal space and  bulging of 
intercostals spaces. Patchy or peribronchial infiltrates suggestive of 
interstitial pneumonia occur in the majority of infants. 
Atelectasis is observed in most infants but consolidation is 
observed in only twenty four percent of patients. 
Minimal pleural fluid can also be present. Thirteen percent of 
infants with illness severe enough to require hospitalization have 
normal chest roengenograms. 
 In general only infants more than one month develop 
syndrome of bronchiolitis. In urban settings the peak age is two 
months but in rural settings it’s a bit later. Antigenic studies shall be 
performed in epithelim for the detection of the virus. Direct 
immunofluorocence is used for the same. 
There are certain settings where the manifestations will be 
severe. When more than one of these settings is present the 
manifestation or outcome is more severe accordingly . 
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RISK FACTORS FOR CLINICAL DETERIORATION IN 
BRONCHIOLITIS30  
                             
Presenting features 
Fast breathing ,decreased oxygen 
saturation and refusal of feeds or 
inadequate hydration 
Younger age Less than 1 year of age 
Coexisting illnesses 
Chronic lung disease, heart 
diseases , and cystic fibrosis as 
well as immunodeficient states 
Preterms Gestation less than thirty six week 
Other factors 
Poverty, overcrowding, smokers 
in the family, hereditary factors 
 
Environment does play a role in modifying the manifestation 
of the disease. Carbonel estrany et al31 did a follow up study in 
preterm’s less than thirty two weeks of gestation and identified the 
additional factors. Inpatients who were admitted were prognosticated  
using these factors – a lesser number of gestational days, age less 
than three months  and exposure to second hand smoking . Similar 
 28 
 
results were arrived too using infants of gestational age thirty three to 
thirty five weeks. 
Overcrowding, exclusive breast feeds given for less than two 
months, wheeze in the family were identified as risk factors for 
inpatient admission in the previous study. Law et al did a follow up 
study in Canada and identified  similar factors as a risk. Boys were 
found to have a higher risk for needing inpatient care. 
It is pretty clear from these studies that the environment and 
population characteristics play a role in the need for inpatient care. 
The environment and the genes also play a role in deciding the 
severity of the disease.  
Second hand smoking too carries an increasing risk of 
inpatient care. Inpatient care for the disease has been on the rise 
primarily because of the better prognosis of patients with other 
comorbidities. And also the increasing use of  pulse oximetry as a 
clinical tool too has played a role in identifying hypoxia and grading 
the severity of the disease. 
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CLINICAL FEATURES: 
Bronchiolitis is more from august to december but it can occur 
at any time of the year . A h/o contact with patients with a cold 
prodrome is often elicited. Initially there will be a running nose , 
cough and refusal of feeds. Fever grade is decided by  the infecting 
agent. 
Most patients have fever at the time of clinical presentation. 
Patients with influenza or parainfluenza as a cause have higher 
grades of fever. Severity can be mild, moderate or severe as graded 
by IAP. Children might present with cyanosis in cases of respiratory 
failure30. Physical examination in cases of bronchiolitis will reveal 
wheeze, crepitations as well as prolongation of the expiratory cycle. 
Other signs can be conjuctival inflammation, acute otitis media 
as well as rhinorrhoea.There can be abdominal distention due do 
hyperinflated lungs. 
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RESPIRATORY DISTRESS ASSESSMENT INSTRUMENT: 
               
The RDAI is used to grade severity in cases of bronchiolitis. 
The tool is also used to observe response to treatment. The highest 
score given is seventeen and the lowest score is zero. Higher the 
score more severe is the level of respiratory distress.(LOWELL ET 
AL 1987)33. 
 Similarly Wang et al34 have come out with a score based on 
wheeze, retractions and general clinical condition. The score ranges 
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from zero to twelve.   Grading of severity –For mild it should be zero 
to four, moderate four to eight, and for severe it should be more than 
nine. 
INVESTIGATIONAL MODALITIES IN BRONCHIOLITIS: 
It is mainly a clinical one. They are undertaken to exclude 
alternative causes of respiratory distress in young children. A mild 
degree of increase in leucocyte count with a normal DC is seen in 
cases of bronchiolitis. Hypoxemia is made out by oxygen saturation 
or by means of bllood gas analysis. Hypercapnoea might be there in 
severe cases of bronchiolitis. Viral detection is by indirect 
fluorescent antibody technique, polymerase chain reaction, RIA or by 
cultures. Viral detection might prevent unwarranted use of 
antimicrobials. 
THERAPY  AND PREVENTIVE ASPECTS: 
There is no gold standard treatment in the case of bronchiolitis. 
It is mainly supportive in nature. There is no indication for the 
pharmaceutic agents used in the management of bronchiolitis. 
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With the advances in modern medicine it is increasingly 
becoming clear that there is minimal role for therapeutic agents and 
health education is being targeted at doctors to make them aware of 
these facts. 
Most patients can be home managed after educating the 
parents regarding the danger signs as well as giving nutritional 
advice. The need for inpatient care is determined by the age of the 
child as well as need for IV fluids , the severity grading and other 
socio-economic factors. 
The therapy of children with bronchiolitis is mainly by means 
of humidified oxygen , maintaining adequate hydration orally or by 
intravenous fluids and restricting the handling of the child. The 
oxygen saturation must be maintained more than ninety two percent . 
Chest physiotherapy is found to be ineffective in the management of 
bronchiolitis35. 
Numerous therapeutic agents are tried in the therapy of 
bronchiolitis. There is no rationality in the  routine use  of 
bronchodilators unless there is a history of asthma. But most 
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clinicians give a trial of bronchodialators even though there is no 
robust evidence in its use in cases of bronchiolitis. 
 The obstruction which is there in cases of bronchiolitis is 
mainly by means of cellular debris as well as mucus, 
bronchoconstriction plays a very minimal role. Moreover the use of 
beta adrenergic bronchodilators have been studied in detail and found 
to have a very minimal role. There is only a temporary improvement 
in clinical use of these agents and the benefits have to be weighed 
against the various disadvantages that they have, including the cost 
of these agents. 
Adrenaline nebulisation is widely used in the treatment of 
bronchiolitis . It mainly acts via the alpha adrenergic receptors 
thereby decreasing  the air way edema which is present in cases of 
bronchiolitis. It decreases airway edema by means of its 
vasoconstrictive effect. However a review of eight RCT’S regarding 
adrenaline nebulisation concluded that   there is no significant 
advantage with its use. It was found to have only a short term benefit 
eventhough it was found to be more effective than salbutamol as well 
as  placebos37. 
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Regarding the role of corticosteroids   meta-analysis was done 
and it was found that it doesn’t impact the duration of in hospital stay 
nor was it found to modify the severity of the disease38. There is no 
recent evidence of steroids as a treatment modality in cases of 
bronchiolitis. Irrespective of the route of administration of drugs 
steroids are found to be in effective in cases of bronchiolitis. 
This is applicable to children presenting in the ED as well as 
those requiring inhospital care. Its role in the setting of 
bronchopulmonary dysplasia is controversial. 
 Children deteriorating might have a ineffective immune 
system or they might have other risk factors which play a role in 
pathogenesis of  the disease. The modality showing some promise in 
treating critically ill cases of bronchiolitis is the use of surfactant in 
the setting of secondary surfactant inactivation. 
3 RCT’S  have been done with surfactants but they weren’t 
comparable due to lack of uniformity in ventilation strategy and a 
meta analysis came to the conclusion that they were found to have a 
non significant decrease in inhospital stay. 
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ROLE OF ANTIVIRAL AGENTS: 
Ribavirin an antiviral agent administered by aerosolized route 
has been used for infants with congenital heart disease or chronic 
lung disease. It is delivered as a small particle aerosol for 18 -20 hrs 
a day.There is no convincing evidence of a positive impact on 
clinically important outcomes such as mortality and duration of 
hospitalization. Likewise there is no support for RSV 
immunoglobulin administration in previously healthy children. 
 However reduction of severity is possible through 
administration of pooled hyper immune RSV intravenous 
immunoglobulin. 
 Other agents which are used include immunoglobulin, a  
mixture of helium and air39, erythropoietin40  and  nitric oxide41 . But 
none of the agents were found to offer benefit in the treatment of 
bronchiolitis. 
Recently the therapy which is  increasingly being tried in the 
management of bronchiolitis is the  Hypertonic saline nebulisation. 
Hypertonic saline nebulisation has been shown to increase the 
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mucociliary transport rates in conditions like cystic fibrosis as well 
as in reactive airway disease. Hypertonic saline nebulisation has been 
tried more and more in cases of bronchiolitis (sarell 200242 ; 
mandelberg 200343 ; Taal44 2006;  and kuzik45 2007) . The way by 
which hypertonic saline offers benefit in bronchiolitis is as follows  
1. Hypertonic saline removes the ionic bonds as well as it decreases 
the cross links in the mucus. Thereby it improves the mucus 
rheological property. It decreases the viscosity of the mucus. 
2. Hypertonic saline causes osmosis of water in to mucus thereby 
improving the mucus rheological property. 3 . Hypertonic saline 
decreases the airway oedema in bronchiolitis(Mandelburg43 2003; 
sarrell42 2002). Hypertonic saline increases the motility of the 
cilia. 
3. Hypertonic saline also induces the sputum formation and 
coughing which  leads to increased clearance thus relieving the 
airway obstruction( Mandelberg43 2003) . These are  various 
theories put forward favouring the use of hypertonic saline 
nebulisation in cases of bronchiolitis. 
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Recent studies from the west have shown benefit in cases of 
bronchiolitis with the hypertonic saline nebulisation both in OPD as 
well as in inpatients. Mandelberg et al showed that in moderately ill 
children hospitalized with bronchiolitis three percent hypertonic 
saline/ 1.5mg adrenaline43 decreases the severity as well as it 
decreases the duration of stay when it was compared with 0.9 n 
saline along with 1.5mg adrenaline. 
Sarell et al showed that in moderately ill cases of bronchiolitis 
treated as op, 3% hypertonic saline along with 5 mg terbutaline was 
found to be beneficial in decreasing the symptomatology when 
compared to 0.9 n saline alongside 5 mg terbutaline42. 
Kuzic et al came to the conclusion that three percent 
hypertonic saline nebulisation is a safe, cost effective and effective 
treatment modality in cases of moderately severe bronchiolitis45. 
IS IT SAFE TO USE? 
Studies have come out saying that a concentration of more 
than seven percent causes bronchospasm46  in cystic fibrosis patients. 
The use of a lesser concentration of hypertonic saline circumvented 
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this problem and also the concomitant use of a bronchodilator has 
alleviated the problem. 
PREVENTIVE ASPECTS: 
Prevention ranges from the use of IV immune globulin to the 
use of respiratory syncytial virus specific polyclonal hyper immune 
gamma globulin ,to the use of murine derived humanized monoclonal 
antibody palivizumab. 
Hyper immune globulin was never popular because of long 
time taken to administer it and also the risk of infection as well as its 
interfering with vaccines which are live attenuated. 
In randomized control studies palivizumab administration at a 
dose of 15 mg per kg decreased the duration of in hospital stay. It 
was administered over a five month period. It decreased the 
inhospital stay in preterms by fifty five percent and forty five percent 
in case of congenital heart diseases which were hemodynamically 
significant. Palivizumab did not provide any advantage with regard 
to mortality. 
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Palivizumab has become the drug of choice in prophylaxis of 
respiratory syncytial virus bronchiolitis  in children more prone to 
the disease. The AAP recommends palivizumab prophylaxis in cases 
of bronchopulmonary dysplasias as well as in infants having heart 
defects and also in preterms less than thirty five weeks gestation47.  
One dose per month is given for 5 months duration. The dose 
is 15 mg /kg given intramuscularly. These recommendations are 
difficult to practice in a country like ours especially considering the 
exorbitant cost of the drug. The number of children requiring RSV 
prophylaxis as per AAP recommendations is quite less. The option is 
not considered as cost effective. 
Some countries restrict palivizumab use to infants with 
bronchopulmonary dysplasia especially during the peak season. 
Despite advances in science due to the complex nature of the agent 
there is no breakthrough in vaccine research. Studies came to a 
standstill when respiratory syncytial virus vaccines produced disease 
in the vaccinees accidentally. 
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Drugs which interfere with the viral replication are being 
investigated and they might one day provide the necessary break 
through. 
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CONCLUSION 
It is quite clear that there being no gold standard management 
strategy in bronchiolitis, the management is largely supportive. 
Because of the prevailing confusion in treatment strategies several 
agents are doing the rounds. And there is no role for bronchodilators, 
corticosteroids or epinephrine nebulisation in a routine manner. In 
this setting hypertonic saline nebulisation can be safe and effective in 
the management of bronchiolitis. Several studies have been done in 
the west and the results are quite positive. Hypertonic saline if 
proven to be effective could have beneficial clinical implications. 
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OBJECTIVES 
To establish the efficacy of nebulized hypertonic saline without 
Bronchodilators in reducing respiratory distress, thereby, clinical 
severity in cases of moderate bronchiolitis. 
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STUDY JUSTIFICATION 
Since the main management of bronchiolitis is largely 
supportive , we would like to work to reduce the respiratory distress , 
thereby , the clinical severity by means of hypertonic saline 
nebulization alone without bronchodilators or epinephrine. 
And this modality of treatment is affordable and practically 
feasible in a developing country like ours. 
 And also not many studies have been conducted in the Indian 
context which in many ways is quite different from the European or 
American context.  
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METHODOLOGY 
Study design: 
Interventional study, Randomised control trial  
Study group: 
Children receiving 3 % hypertonic saline along with  
supportive therapy. 
Control group: 
Children receiving supportive therapy alone. 
Study period: 
Protocol preparation-Dec 2010-feb 2011 
Sample Size : 116 
Data collection:  
March 2011-august 2012 
Data analysis and manuscript preparation: 
Sep 2012 - Nov- 2012 
Submission of report:  
December -2012 
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DEFINITIONS 
 
Case definition: 
Bronchiolitis is defined as per American academy of pediatrics 
definition as a constellation of clinical symptoms and signs like 
rhinorrhoea, cough , wheezing , tachypnoea , and increased 
respiratory effort  manifested as grunting , nasal flaring and 
intercostals and or subcostal retractions in children less than two 
years of  age. 
Moderate bronchiolitis is characterized by , feeding difficulty, 
moderate respiratory distress with some chest wall retractions and 
nasal flaring and oxygen saturation less than 92 % which is 
correctable with oxygen. 
Respiratory distress was defined by intercostal, subcostal or 
supra sternal retractions. 
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Child considered to be tachypnoeic-Based on World health                              
organization guidelines. 
1. 60 per minute in age less than two months. 
2. 50 per minute in age two to twelve months. 
3. 40 per minute in age more than one year. 
 
Inclusion criteria: 
Hospitalised children in a tertiary care hospital in Chennai with 
a clinical diagnosis of moderate bronchiolitis. 
Exclusion criteria:  
 Presence of complicating underlying illnesses. 
 Bronchopulmonary dysplasia or chronic lung disease. 
 Neuromuscular impairment. 
 Congenital heart disease. 
 Treatment with corticosteroids 
 Previous episode of Wheeze 
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Children who met the inclusion criteria  were recruited for the 
study. Hundred chidren enrolled according to the desired sample size. 
Written consent was documented from all the parents before 
enrolling them in to study. 
Ethical committee approval was obtained from the institutional 
ethics committee. 
Conflict of interest: Nil 
Financial support: Nil 
Patients were randomized in to two groups based on computer 
generated random numbers. 
The eligible children who were recruited were randomized in to 
two groups using random table in blocks of ten. 
Study group received 3% hypertonic saline nebulisation 3 ml 
8th hourly in addition to supportive therapy . The nebulisations were 
continued till discharge. 
Children in control group received supportive therapy alone. 
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Nebulisations were administered using nebulisation chambers 
which are routinely available in our wards. The nebulisations were 
administered along with humidified oxygen. Humidified oxygen was 
given at a rate of six litres per minute. 
Children were admitted to the study  within twenty four hours 
of admission. The history was obtained from the mother and the 
chidren were examined at the time of entering in to the study as well 
as everyday. Vital signs were recorded in all the patients. Children 
were observed for cyanosis , retractions as well as anemia. 
Detailed examination of the respiratory system was also done. 
A complete blood count and a x ray chest was done for all the 
children. All the children were given oxygen and IV fluids were 
administered for children who did not tolerate oral feeds. 
Length of stay in the hospital was taken as the primary 
outcome. 
Cough resolution time and wheeze resolution time were taken 
as secondary outcomes in the study. 
Adverse effects were recorded for the study group. 
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The length of stay was recorded using a previously validated 
method. Every day the patients were examined for four conditions for 
which they were retained in the study. 
1. Child on drugs for the disease. 
2. Child administered humidified o2 or IVF because of the disease. 
3. Children retained because of co- morbid conditions. 
4. Children who could not be sent home because of conditions at 
their home. 
Hospital days were recorded only when the reason was 
administration of drugs or humidified o2 administration. 
Time of discharge will be decided by the treating consultant. 
 
Criteria for discharge: 
1. Afebrile and no clinical signs of clinical respiratory distress . 
2. Spo2 should be more than ninety six percent and the child 
should be comfortable in room air. 
3. Feeding should be possible orally. 
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Statistical method: 
All data entered in data collection form are entered in excel 
spread sheet. Descriptive statistical analysis was done in the 
study.Continuous measurement is represented by mean plus or minus 
S.D 
Categorical measurements were represented by percentage. 
Significance was assessed by five percent level of significance. 
 
Statistical software: 
For stastistical analysis SPSS  version 16 is used 
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RESULTS 
During the study 116 patients were admitted in to the study 
with a diagnosis of bronchiolitis with moderate severity. Of those 108 
children were included 8 were not included due to previous history of 
wheeze. Amongst the 108 patients eight were excluded due to the 
prior treatment with corticosteroids.At last 100 children were 
analysed and  randomization was done for them and they were 
randomized in to two groups of 50 each.The study group were 
administered 3% hypertonic saline nebulisation along with supportive  
care were 50 in number and the controls who received supportive care 
alone contained 50 children. 
 
 
 
 
 
 
 
 
 
108 children were eligible for 
the study. 
Randomisation (n=100) 
Received 3 % hypertonic saline 
nebulisation along with supportive therapy 
(n=50) 
Received supportive therapy 
alone.(n=50) 
8 were excluded due 
to history of 
treatment with 
corticosteroids 
116 chidren with clinical 
diagnosis of moderately severe 
bronchiolitis. 
8 had history of 
previous wheeze 
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Supportive therapy included the administration of humidified 
oxygen and intravenous fluids. 
POPULATION CHARACTERISTICS: 
AGE DISTRIBUTION OF THE ENROLLED CHILDREN. 
 
   Age 
Total 
   0-6m 7-12m 13-24m 
Group 
Case 
Count 2 27 21 50 
% within 
Group 
4.0% 54.0% 42.0% 100.0% 
Control 
Count 1 26 23 50 
% within 
Group 
2.0% 52.0% 46.0% 100.0% 
Total 
Count 3 53 44 100 
% within 
Group 
3.0% 53.0% 44.0% 100.0% 
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p value =0.801 
In  study done by us the age was comparable in the study and 
control groups. 
The majority were were in the 7-12 month age group. 
 
 
 
 
 
 
7-12m 
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GENDER DISTRIBUTION: 
   Sex 
Total 
   Male Female 
Group 
Case 
Count 28 22 50 
% within Group 56.0% 44.0% 100.0% 
Control 
Count 31 19 50 
% within Group 62.0% 38.0% 100.0% 
Total 
Count 59 41 100 
% within Group 59.0% 41.0% 100.0% 
 
In this study males were more commonly affected than 
females. 
The male to female ratio was 1.43:1 
Male is to female ratios was comparable between the study 
group and the  control group 
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         P value = 0.542  
 
Amongst cases 56 % were males and remaining 40% were 
females. 
Amongst controls 62 % were males and remaining 32 % were 
females. 
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CHEST X-RAY 
 
   X_ray 
Total 
   Normal BHI 
Group 
Case 
Count 26 24 50 
% within 
Group 
52.0% 48.0% 100.0% 
Control 
Count 41 9 50 
% within 
Group 
82.0% 18.0% 100.0% 
Total 
Count 67 33 100 
% within 
Group 
67.0% 33.0% 100.0% 
 
Amongst all cases clinically diagnosed as moderate 
bronchiolitis 67 % had normal X rays , only 33 % had the classical 
feature of bilateral hyperinflation. 
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p value = 0.003 
Amongst the study group there was a higher proportion of 
children with bilateral hyper inflation. 
Hence the study group and the control group was not 
comparable with respect to bilateral hyper inflation in chest xray. 
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TOTAL BLOOD COUNT 
   Blood_cnts 
Total 
   Normal Abnormal 
Group 
Case 
Count 48 2 50 
% within Group 96.0% 4.0% 100.0% 
Control 
Count 48 2 50 
% within Group 96.0% 4.0% 100.0% 
Total 
Count 96 4 100 
% within Group 96.0% 4.0% 100.0% 
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Amongst cases getting 3 % hypertonic saline nebulizations 4 
percent had abnormal blood counts. 
Similarly amongst controls receiving supportive therapy 4 
percent had abnormal blood counts. 
The two groups were comparable with regard to abnormal 
blood counts. 
Only the upper and lower levels of age appropriate total 
leukocyte count was taken in to consideration.  
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HUMIDIFIED OXYGEN ADMINISTRATION 
   O2 
Total 
   Yes 
Group 
Case 
Count 50 50 
% within 
Group 
100.0% 100.0% 
Control 
Count 50 50 
% within 
Group 
100.0% 100.0% 
Total 
Count 100 100 
% within 
Group 
100.0% 100.0% 
 
Humidified oxygen was administered to all the cases in the 
study as well as in the control group as part of the supportive therapy. 
Hence the two groups were comparable with regard to oxygen 
administration. 
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ADMINISTRATION OF INTRAVENOUS FLUIDS. 
   IV_fluids 
Total    No Yes 
Group Case Count 47 3 50 
% within 
Group 
94.0% 6.0% 100.0% 
Control Count 49 1 50 
% within 
Group 
98.0% 2.0% 100.0% 
Total Count 96 4 100 
% within 
Group 
96.0% 4.0% 100.0% 
     
 
Six percent of children in the group receiving hypertonic saline 
with supportive therapy required intravenous fluids. 
Two percent of children receiving supportive therapy alone 
developed the need for intravenous fluids. 
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P VALUE=0.617 
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CHILDREN ON ORAL FEEDS 
   Oral 
Total 
   Yes No 
Group 
Case 
Count 47 3 50 
% within 
Group 
94.0% 6.0% 100.0% 
Control 
Count 49 1 50 
% within 
Group 
98.0% 2.0% 100.0% 
Total 
Count 96 4 100 
% within 
Group 
96.0% 4.0% 100.0% 
 
94 %  of the cases were able to take oral feeds in the group 
receiving hypertonic saline nebulisation. 
98 % of the chidren receiving supportive therapy alone were 
able to take oral feeds 
Overall 96 % of the children were able to take oral feeds and the 
remaining 4 % were given intravenous fluids.  
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ORAL FEEDS 
 
P value = 0.617 
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COUGH RESOLUTION TIME 
   CR_time 
Total 
   3-4 days 1-2days 
Group 
Case 
Count 24 26 50 
% within 
Group 
48.0% 52.0% 100.0% 
Control 
Count 37 13 50 
% within 
Group 
74.0% 26.0% 100.0% 
Total 
Count 61 39 100 
% within 
Group 
61.0% 39.0% 100.0% 
 
Amongst cases receiving 3 % hypertonic saline along with 
supportive therapy in 48 % of cases the cough got resolved in 3-4 
days.In 52 % of the cases the cough got resolved in 1-2 days. 
Amongst children receiving supportive therapy alone in 74 % of the 
cases the cough resolved in 3-4 days. In remaining 26 % the cough 
got resolved in 1-2 days. 
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Overall in both the groups, in 61 % of the cases the cough got 
resolved in 3-4 days. In 39 % of the cases the cough got resolved in 
1-2 days 
 
 
 
P value = 0.014   statistically significant 
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WHEEZE RESOLUTION TIME 
   WR_time Total 
   1-2days 3-4days 5-6days 
Group 
Case 
Count 30 18 2 50 
% within 
Group 
60.0% 36.0% 4.0% 100.0% 
Control 
Count 11 39 0 50 
% within 
Group 
22.0% 78.0% .0% 100.0% 
Total 
Count 41 57 2 100 
% within 
Group 
41.0% 57.0% 2.0% 100.0% 
 
Amongst children receiving hypertonic saline along with 
supportive therapy in 60 % of cases the wheeze got resolved in 1-2 
days. In 36 % of children the wheeze got resolved in 3-4 days. In 
remaining  4 % the wheeze got resolved in 5-6 days. 
 Amongst children receiving supportive therapy alone in 22 % 
of the cases the wheeze got resolved in 1-2 days. In 78 % of the cases 
the wheeze got resolved in 3-4 days. 
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Overall  in 41 % of the cases the wheeze got resolved in 1-2 
days. In 57 % of the cases the wheeze resolved in 3-4 days . In the 
remaining 2 % of the cases the wheeze got resolved in 5-6 days. 
 
 
 
P value = 0.000 
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ADVERSE EFFECT: 
   Adv_effect 
   Nil 
Group Case 
Count 50 
% within Group 100.0% 
 
No adverse effects were observed in the group receiving 3 
% hypertonic saline nebulisation along with supportive therapy. 
Supportive therapy included oxygen administration and IV fluids. 
 
T-Test 
 
LENGTH OF STAY:  
 
Group Statistics 
 Group N Mean 
Std. 
Deviation 
P-value 
Dur_Stay 
Case 50 4.76 .657 
0.235 
Control 50 4.90 .505 
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The mean duration in the group receiving 3 % hypertonic saline 
along with supportive therapy was found to be  4.76±0.567 days. 
The mean duration in the group receiving supportive therapy 
alone was found to be 4.90±0.505 days. 
However this was not found to be statistically significant. 
P value = 0.235 
 
 
 
P value = 0.235 
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The primary outcome  parameter  considered  in this study 
was duration of hospital stay. 
The secondary outcome parameters which were considered 
in this study was cough resolution time and wheeze resolution 
time. 
The adverse effects were observed in the group receiving 3 
% hypertonic saline nebulisation. 
The mean duration of hospital stay in the group receiving 3 
% hypertonic saline nebulisation along with supportve therapy was 
found to be 4.76±0.567 days. 
The mean duration of hospital stay in the group receiving 
supportive therapy alone was found to be 4.90±0.505 days. 
There was a 3.9 percentage reduction in length of stay in the 
hypertonic saline group compared to the control group which 
received supportive therapy alone. 
But these findings were not statistically significant. 
The cough resolution time was shorter  in the 3 % 
hypertonic saline group compared to the controls receiving 
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supportive therapy alone. 
The reduction in the cough resolution time was statistically 
significant. 
The wheeze resolution time was also shorter in the group 
receiving 3% hypertonic saline along with supportive therapy as 
compared to the group receiving  supportive therapy. 
The difference in the wheeze resolution time was 
statistically significant. 
There were no adverse effects observed in the group 
receiving 3 % hypertonic saline along with supportive therapy. 
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DISCUSSION 
Bronchiolitis is a common cause of lower respiratory 
infection in the age group less than two years of age. Mostly it is 
due to a viral etiology. Usually it gets resolved spontaneously and 
respiratory syncytial virus is the commonest agent contributing to 
almost 50 % of the disease 
A study was done in India48 regarding the incidence and the 
pattern of infection and it was found to be the same as in any other 
part of the world. The disease has a peak incidence mainly during 
the months of september through january, but it can occur at any 
time of the year. In the study done in our hospital the incidence 
was maximum during the winter months but sporadic cases did 
occur through out the year. 
This fact is supported by the study done by John tj et al48 
and yeleokar et al49  who studied the seasonal pattern of the disease 
caused by respiratory syncytial virus. 
Bronchiolitis usually affects young children and the disease 
is more severe when it occurs in infants less than six months of 
age. In our study all chidren less than two years were admitted ( 
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range 0-24 months). 
Children in the  6-12 months  category constituted the 
majority in our study. They accounted for 53 %  of the cases.This 
was in contrast to a cohort study done by Fjaerli et al regarding the 
incidence and risk factors in respiratory syncytial virus disease. 
Bronchiolitis is more common in males compared to 
females. In or study too a male predominance was observed 
accounting for 59 % of all admissions. The male: female ratio in 
our study was found to be 1.43:1. This observation is consistent 
with the work done by John tj et al in south india. They studied the 
etiological factors, incidence , risk factor and clinical presentation 
of respiratory tract infection in children and came to the conclusion 
that males were more commonly affected than females.  In their 
study the male is to female ratio was found to be 1.6:1. 
Fjaerli et al50 too did a similar study in Norway and came 
out with the finding that  there was male predominance and the 
male is to female ratio was 1.42:1. Simoes EAF51  in his study 
done in America studied the risk factors which lead to a severe 
RSV disease and came out with the findings that respiratory 
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syncytial virus infection was more common in boys than in girls 
and the ratio was 2:1. Also boys were found to be affected in a 
more severe manner compared to girls. 
Bronchiolitis is mainly a clinical diagnosis and 
investigations are not necessary to diagnose the disease. And blood 
counts are usually not done. They are done if there is atypical 
presentation and also to rule out other causes. 
In our study 4 % in the group receiving hypertonic saline 
along with supportive therapy and 4 % in the group receiving 
supportive therapy had abnormal total blood counts . In our study 
all children who had abnormal total blood counts had increased 
total leucocyte count when compared to age appropriate values and 
they were equally distributed in both the groups. The groups were 
comparable in this respect. 
In Bronchiolitis there will usually be hyperinflation of lungs 
and atelectasis. In our study we found that majority of the x-rays 
were normal 67 % and in the remaining 33 % there was bilateral 
hyperinflation or flattening of diaphragm or prominence of 
retrosternal space or bulging of intercostal spaces or a combination 
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of these findings. 
 Our observations are in contrast to a study done by scuh et 
al who came out with the findings that majority of the cases of 
bronchiolitis had the radiological feature characteristic of 
bronchiolitis. The study was a follow up study and he studied the 
utility of chest x-ray to diagnose bronchioli. 
In our study the primary outcome measured was the length 
of stay. The length of stay was arrived at by measuring the 
duration required to attain discharge criteria. The mean duration of 
length of stay in our hospital amongst the group receiving 3 % 
hypertonic saline and supportive therapy was 4.76±0.657.  
This was in contrast to the study done by Mandelbeg et al43 , 
Tal et al44 , and Kuzik et al45.  In the study done by Mandelber et al 
the mean duration of hospital stay was found to be 3.5. In the study 
done by Tal et al the mean duration of hospital stay was found to 
be 3.1. Similarly in a study done by kuzik et al the mean duration 
of hospital stay was found to be 3.1. 
 This difference in lengthof stay could be explained by the 
fact that in different centres the severity could have been different 
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as well as the role of inter observer variation in grading of severity 
cannot be underplayed. 
 In the 3 % hypertonic saline group the duration of stay was 
slightly lesser compared to the group which received supportive 
therapy alone. But this difference did not attain statistical 
significance.  
By trying  3 % hypertonic saline we found that there was a  
3.9 percentage reduction in length of stay in the group that 
received 3 % hypertonic saline along with supportive therapy 
compared to the group that received supportive therapy alone. 
However this was not statistically significant. 
These findings are in contrast to studies done by 
Mandelberg et al43 , kuzik et al44 and Tal et al45. Taal et al arrived 
at a mean reduction of  0.9  days (26%)His findings were 
statistically significant.Kuzik et al observed a 26 % reduction in 
length of stay with the use of 3% hypertonic saline nebulisations. 
Maandelberg et al43 in his study usin 3 % hypertonic saline 
nebulisations in cases of mild and moderate bronchiolitis arrived at 
a finding of 1 day reduction  in length of stay (25%) .The 
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difference in observations could be attributed to the fact that in our 
study only moderate cases of bronchiolitis were included. 
The secondary outcomes measured in our study was cough 
resolution time. In our study the cough resolution time in the group 
receiving 3 % hypertonic saline along with supportive therapy was 
lesser than the controls receiving supportive therapy alone. 
And this difference in cough resolution time between the 
two groups was statistically significant. 
The other secondary outcome measured in our study was 
wheeze resolution time. The wheeze resolution time in the group 
receiving 3 % hypertonic saline group was lesser compared to the 
controls who received supportive therapy alone. And this finding 
was statistically significant. 
In general the use of 3% hypertonic saline is considered to 
be fairly safe. Some studies conducted in patients suffering from 
cystic fibrosis have reported bronchospasm as an adverse effect. 
But lesser concentrations of hypertonic saline have been studied in 
bronchiolitis and found to be safe.  
In our study no adverse effects were noted due to 3 % hyper 
 79 
 
tonic saline administration.  The same was observed in studies 
done by Mandelberg et al43 ,kuzik et al45 and Tal et al44 .They did 
not observe any adverse effects in their use of 3 % hypertonic 
saline nebulisation. 
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STUDY LIMITATIONS 
As we included only moderate cases of bronchiolitis , the 
role of hypertonic saline in severe bronchiolitis wherein other 
factors might play a role is unclear. 
Since bronchiolitis is mainly a clinical diagnosis , the role of 
intraobserver variation cannot be underplayed. 
Because of the small sample size a significant reduction in 
duration of hospital stay could not be ascertained. 
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SUMMARY 
3 % hypertonic saline  nebulization does not reduce the 
length of stay in cases of moderate bronchiolitis in a significant 
manner. 
3 % Hypertonic saline nebulizations decrease the clinical 
severity by decreasing the cough resolution and wheeze resolution 
time in children admitted with moderate bronchiolitis. This was 
statistically significant. 
3 % Hypertonic saline administration in children did not 
produce any adverse effects and it is safe to use in children 
diagnosed with bronchiolitis. 
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CONCLUSIONS 
In conclusion  our study suggests that 3 % hypertonic saline  
helps to reduce the cough resolution and wheeze resolution time 
thereby decreasing the clinical severity in hospitalized patients 
admitted with a diagnosis of moderately severe bronchiolitis.    
Further studies are  required to see if 3 % hypertonic saline 
has an effect on the length of stay. 
3 % hypertonic saline was found to be safe in treating  
bronchiolitis    in children.  
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“EFFICACY OF 3% HYPERTONIC SALINE NEBULISATION 
IN CHILDREN HOSPITALIZED WITH MODERATE 
BRONCHIOLITIS” 
 
 
1. 
Patient name (in Caps) 
 
          
 
Sex   1. Male               2. Female   
 
2. Age                        YY                       MM  
3. 
Date of admission    
  
 
 
Date of discharge 
 
 
 
4. 
Father’s  Name       
          
 
Qualification :   1. Illiterate 2 .Primary (≤ grade 5) 
3. Secondary (grade 5-12)     4. Graduate 
 
Occupation: 1. Unemployed    2. Unskilled labour    
                     3. Skilled labour       4. Business        
                     5. Professional          6. Others 
 
5. 
Mother’s Name 
                 
 
Qualification :  1. Illiterate  2.Primary (≤  grade 5) 
3. Secondary (grade 5-12)     4. Graduate 
 
Occupation: 1. Unemployed  2. Unskilled labour    
                     3. Skilled labour       4. Business        
                     5. Professional          6. Others 
 
6. Residence              1. Chennai Corporation    2. Others 
7. 
Address                              
 
Door No: 
 
Street : 
WD/Town 
State: 
Pin Code: 
      
 
8. 
Socio Economic Class 
Modified Kuppyswamy scale 
 
 
Specify-- 
 
 CLINICAL HISTORY 
9.  Fever 
 
1.  Yes                       2.  No 
 
 a.                                If  Yes Duration 
 b.                                 Amplitude 1.Low      2. Moderate  3. High 
 c                                  Periodicity 1.Continuous  2. Intermittent  3. Remittent 
 d.                                  Chillis 
 
1.  Yes                       2.  No 
 
10.  Cough & Cold 
 
1.Yes                          2. No 
 
Duration----- 
 
 
    
 
 
 
  
 
11.  H/O Breathlesness 
 
1.Yes                          2. No 
 
Duration 
 
12.  H/O Cyanosis 
 
1.Yes                           2. No 
 
Duration 
13.  H/O Chest retractions 
 
1.Yes                         2. No 
 
Duration 
14.  H/O Noisy Breathing 
 
1.Yes                          2. No 
 
Duration 
15.  Refusal of feeds 
 
1.Yes                          2. No 
 
Duration 
16.  H/O bad CRP 
 
1.Yes                           2. No 
If yes Specify 
a.Nasal blowing                     b.Oil instillation 
c.Sambrani fumes                  d.Others 
17.  Skin Infections  1.Yes                          2. No 
18.  Ear discharge  1.Yes                          2. No 
19.  H/O of Vomiting 
 
1.Yes                             2. No 
 
Duration 
20.  Others    Specify   
21.  
Immunisation 
a. National immunization schedule 
 
1. Up to Age    2. Not upto age  3. Unimmunized 
4. Not known 
 
 b. Others    Specify  
PAST HISTORY 
22.  H/O Measles 
When – 
Treatment details 
 
 
23.  H/O of Hospitalisation 
 
1.Yes                              2. No 
Duration ---- 
Diagnosis 
 
 
24.  H/O of seizures 
 
1.Yes                                2. No 
 
If Yes , No.of episodes /year---- 
Treatment details 
 
25.  Developmental delay 1.Present         2.Absent 
  
 
TREATMENT HISTORY  
26.  X-ray chest taken 
 X-ray report – 
1. 
                                   
27.  Antibiotics 1. Yes 2. No 
 
EXAMINATION 
 
28. Weight                  - Height                               - 
29. Sensorium 1.  Normal           2.  Altered 
30. Nutritional status ( specify)   
31. Pulse Rate- 
32. BP  ( mm of Hg )  
33. RS  
34. Respiratory Rate 
1. >40 
2. >50 
3. >63 
35. Work of Breathing 1.Grunt           2. Stridor            3.Retractions 
36. Tracheal position 1.midline         2.Right               3.Left 
  RIGHT LEFT AREAS 
37. Breath sounds    
38. If any other findings  ( specify )  
39. CVS 1. Normal          2. Abnormal                 
 If any findings  ( specify )  
40. Abdomen 1. Normal           2. Abnormal                 
 If any findings  ( specify )  
41. CNS 1. Normal            2. Abnormal 
42. If any findings  ( specify)  
 
INVESTIGATIONS 
 
 Blood Count  
43.  Total Count                       Cells/cubic mm 
44.   X ray   Chest  Date Report 
 I    
 II    
 
 
 
 
 
 
 
 
 
 
 
  
 
TREATMENT 
 
45. Oral feeds started on  
46. IV fluids 1.  Yes     2.  No 
47. 
f yes Specify 
 
 
48. HUMIDIFIED OXYGEN ADMINISTRATION             1.  Yes          2. No 
49. NEBULISED HYPER TONIC SALINE      -     3%  8th hourly                                                                   1.  Yes          2. No 
 
 
 Crosstabs 
 
Group * Age 
Crosstab 
   Age 
Total    0-6m 6-12m 13-24m 
Group Case Count 2 27 21 50 
% within Group 4.0% 54.0% 42.0% 100.0% 
Control Count 1 26 23 50 
% within Group 2.0% 52.0% 46.0% 100.0% 
Total Count 3 53 44 100 
% within Group 3.0% 53.0% 44.0% 100.0% 
P=0.801 
 
Group * Sex 
Crosstab 
   Sex 
Total    Male Female 
Group Case Count 28 22 50 
% within Group 56.0% 44.0% 100.0% 
Control Count 31 19 50 
% within Group 62.0% 38.0% 100.0% 
Total Count 59 41 100 
% within Group 59.0% 41.0% 100.0% 
P=0.542 
 
Group * X_ray 
 
Crosstab 
   X_ray 
Total    Normal BHI 
Group Case Count 26 24 50 
% within Group 52.0% 48.0% 100.0% 
Control Count 41 9 50 
% within Group 82.0% 18.0% 100.0% 
Total Count 67 33 100 
% within Group 67.0% 33.0% 100.0% 
P=0.003 
Group * Blood_cnts 
Crosstab 
   Blood_cnts 
Total    Normal Abnormal 
Group Case Count 48 2 50 
% within Group 96.0% 4.0% 100.0% 
Control Count 48 2 50 
% within Group 96.0% 4.0% 100.0% 
Total Count 96 4 100 
% within Group 96.0% 4.0% 100.0% 
P=1.000 
 Group * O2 
Crosstab 
   O2 
Total    Yes 
Group Case Count 50 50 
% within Group 100.0% 100.0% 
Control Count 50 50 
% within Group 100.0% 100.0% 
Total Count 100 100 
% within Group 100.0% 100.0% 
 
Group * IV_fluids 
 
Crosstab 
   IV_fluids 
Total    No Yes 
Group Case Count 47 3 50 
% within Group 94.0% 6.0% 100.0% 
Control Count 49 1 50 
% within Group 98.0% 2.0% 100.0% 
Total Count 96 4 100 
% within Group 96.0% 4.0% 100.0% 
P=0.617 
 
Group * Oral 
 
Crosstab 
   Oral 
Total    Yes No 
Group Case Count 47 3 50 
% within Group 94.0% 6.0% 100.0% 
Control Count 49 1 50 
% within Group 98.0% 2.0% 100.0% 
Total Count 96 4 100 
% within Group 96.0% 4.0% 100.0% 
P=0.617 
Group * CR_time 
 
Crosstab 
   CR_time 
Total    3-4 days 1-2days 
Group Case Count 24 26 50 
% within Group 48.0% 52.0% 100.0% 
Control Count 37 13 50 
% within Group 74.0% 26.0% 100.0% 
Total Count 61 39 100 
% within Group 61.0% 39.0% 100.0% 
P=0.014 
Group * WR_time 
 
Crosstab 
   WR_time 
Total    1-2days 3-4days 5-6days 
Group Case Count 30 18 2 50 
% within Group 60.0% 36.0% 4.0% 100.0% 
Control Count 11 39 0 50 
% within Group 22.0% 78.0% .0% 100.0% 
Total Count 41 57 2 100 
% within Group 41.0% 57.0% 2.0% 100.0% 
P=0.000 
 
 
 
Group * Adv_effect 
 
Crosstab 
   Adv_effect 
Total    Nil 
Group Case Count 50 50 
% within Group 100.0% 100.0% 
Control Count 50 50 
% within Group 100.0% 100.0% 
Total Count 100 100 
% within Group 100.0% 100.0% 
 
 
T-Test 
 
[DataSet1]  
 
Group Statistics 
 Group N Mean Std. Deviation P-value 
dur_stay Case 50 4.76 .657 
0.235 
Control 50 4.90 .505 
 
 
 
 
